MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma L39373 Final LCD - Effective August 06, 2023

This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories). Responses to comments received may be found as a link at the bottom of the final LCD.

Medicare Coverage Database (MCD) Number/Contractor Determination Number: L39373

LCD Title: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

Effective Date: August 06, 2023

Summary of LCD: The purpose of this test is to assist dermatopathologists to arrive at the correct diagnosis of melanoma versus non-melanoma when examining skin biopsies. This Medicare contractor will provide limited coverage for molecular Deoxyribonucleic acid (DNA)/Ribonucleic acid (RNA) assays that aid in the diagnosis or exclusion of melanoma from a biopsy when outlined clinical conditions are met.

Visit the Proposed LCDs webpage to access this LCD.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )